Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcello Arca

Showing results (191-200 of 212) with videos related to

Pageof 22
Sort By:
Arteriosclerosis, Thrombosis, and Vascular Biology|July 5, 2005
The molecular basis of lecithin:cholesterol acyltransferase deficiency syndromes: a comprehensive study of molecular and biochemical findings in 13 unrelated Italian familiesLaura Calabresi, Livia Pisciotta, Anna Costantin, et al.
Giornale Italiano Di Cardiologia (2006)|June 26, 2025
[The BRING-UP Prevention study: a national participation model for the improvement of secondary prevention strategies]Furio Colivicchi, Francesco Orso, Fabrizio Oliva, et al.
Atherosclerosis|July 7, 2018
Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score"Philippe Moulin, Robert Dufour, Maurizio Averna, et al.
Giornale Italiano Di Cardiologia (2006)|September 28, 2023
[How to overcome barriers to implementation of prevention and management strategies of atherosclerotic cardiovascular disease through lipid-lowering therapy]Marcello Arca, Maurizio Averna, Claudio Borghi, et al.
Giornale Italiano Di Cardiologia (2006)|March 24, 2020
[Appropriateness criteria for the management of lipid-lowering therapy with alirocumab in high cardiovascular risk patients. The opinion of a multidisciplinary group of Italian experts]Maddalena Lettino, Alberto Zambon, Giuseppe Musumeci, et al.
European Heart Journal|May 2, 2023
2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidanceMarina Cuchel, Frederick J Raal, Robert A Hegele, et al.
The Lancet. Diabetes & Endocrinology|October 5, 2019
Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statementRobert A Hegele, Jan Borén, Henry N Ginsberg, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|February 8, 2026
Sustainable and Effective Lipid-Lowering Management: Prevention Strategies from the BRING-UP Prevention StudyFurio Colivicchi, Pier Luigi Temporelli, Francesco Fattirolli, et al.
European Heart Journal|May 7, 2025
Clinical staging to guide management of metabolic disorders and their sequelae: a European Atherosclerosis Society consensus statementStefano Romeo, Antonio Vidal-Puig, Mansoor Husain, et al.
Atherosclerosis. Supplements|May 21, 2014
The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practiceNaveed A Sattar, Henry Ginsberg, Kausik Ray, et al.
Pageof 22

Showing results (191-200 of 212) with videos related to

Sort By:
Pageof 22
Arteriosclerosis, Thrombosis, and Vascular Biology|July 5, 2005
The molecular basis of lecithin:cholesterol acyltransferase deficiency syndromes: a comprehensive study of molecular and biochemical findings in 13 unrelated Italian familiesLaura Calabresi, Livia Pisciotta, Anna Costantin, et al.
Giornale Italiano Di Cardiologia (2006)|June 26, 2025
[The BRING-UP Prevention study: a national participation model for the improvement of secondary prevention strategies]Furio Colivicchi, Francesco Orso, Fabrizio Oliva, et al.
Atherosclerosis|July 7, 2018
Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score"Philippe Moulin, Robert Dufour, Maurizio Averna, et al.
Giornale Italiano Di Cardiologia (2006)|September 28, 2023
[How to overcome barriers to implementation of prevention and management strategies of atherosclerotic cardiovascular disease through lipid-lowering therapy]Marcello Arca, Maurizio Averna, Claudio Borghi, et al.
Giornale Italiano Di Cardiologia (2006)|March 24, 2020
[Appropriateness criteria for the management of lipid-lowering therapy with alirocumab in high cardiovascular risk patients. The opinion of a multidisciplinary group of Italian experts]Maddalena Lettino, Alberto Zambon, Giuseppe Musumeci, et al.
European Heart Journal|May 2, 2023
2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidanceMarina Cuchel, Frederick J Raal, Robert A Hegele, et al.
The Lancet. Diabetes & Endocrinology|October 5, 2019
Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statementRobert A Hegele, Jan Borén, Henry N Ginsberg, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|February 8, 2026
Sustainable and Effective Lipid-Lowering Management: Prevention Strategies from the BRING-UP Prevention StudyFurio Colivicchi, Pier Luigi Temporelli, Francesco Fattirolli, et al.
European Heart Journal|May 7, 2025
Clinical staging to guide management of metabolic disorders and their sequelae: a European Atherosclerosis Society consensus statementStefano Romeo, Antonio Vidal-Puig, Mansoor Husain, et al.
Atherosclerosis. Supplements|May 21, 2014
The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practiceNaveed A Sattar, Henry Ginsberg, Kausik Ray, et al.
Pageof 22